2019 ACR/ARP Annual Meeting

November 8-13, 2019. Atlanta, GA.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 383

Retroperitoneal Fibrosis- a Single Center Experience
Abstract Number: 1783

Reversible Dysregulation of Renal Circadian Rhythm in Lupus Nephritis
Abstract Number: 1757

Review of Effectiveness of an Intensive Rehabilitation Programme in Managing Strength, Pain and Function in 123 Young People with Rheumatological Conditions
Abstract Number: 699

Revising the SLEDAI-2K to Include Additional Constitutional Symptoms to More Accurately Assess Lupus Disease Activity
Abstract Number: 582

Rheumacheck – Spondyloarthritis: Comprehensive Fast-track Diagnosis Program. What Benefits Does It Offer in a Developing Country?
Abstract Number: 2125

Rheumatic Fever in a Tertiary Medical Center – 25 Years of Follow Up
Abstract Number: 2158

Rheumatic Immune Related Adverse Events Associated with Cancer Immunotherapy: A Nationwide Multi-centre Canadian Cohort from the Canadian Research Group of Rheumatology in Immuno-oncology (CanRIO)
Abstract Number: 2138

Rheumatic Immune-related Adverse Effects from Checkpoint Inhibitor Immunotherapy in Patients with Solid Tumors in a Latin American Population
Abstract Number: 2139

Rheumatic Immune-Related Adverse Events Associated with Treatment with Immune Checkpoint Inhibitors: A Multicenter Study of 38 Cases
Abstract Number: 1810

Rheumatic Toxicities Associated with Immune Checkpoint Inhibitors: An Observational, Retrospective, Pharmacovigilance Study
Abstract Number: 1184

Rheumatoid Arthritis Activity Assessment with Cellphone Thermal Camera Imaging Compared to Clinical and Ultrasound Assessments
Abstract Number: 260

Rheumatoid Arthritis Associated with Longer Hospital Stays in Patients Admitted with Venous Thromboembolism: A Nationwide Analysis 2010-2014
Abstract Number: 2228

Rheumatoid Arthritis Disease Activity Is Associated with Low Femoral Neck Bone Mineral Density in a Diverse Cohort of Patients
Abstract Number: 1898

Rheumatoid Arthritis in Pregnancy and Offspring School Performance. a Danish Nationwide Register-Based Study
Abstract Number: 877

Rheumatoid Arthritis Patients’ Perspectives on Tapering of Biologics: A Qualitative Study

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].